+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tachyphylaxis to beta2-agonists in Spanish asthmatic patients could be modulated by beta2-adrenoceptor gene polymorphisms



Tachyphylaxis to beta2-agonists in Spanish asthmatic patients could be modulated by beta2-adrenoceptor gene polymorphisms



Respiratory Medicine 100(6): 1072-1078



The study of determinants of asthma is a subject of much interest currently, especially the pharmacogenetic aspects of asthma management. Genetic polymorphisms affecting amino-acids at positions 16 and 27 within beta(2)-adrenoceptor (beta(2)AR) gene have been implicated in the asthma phenotypes and influence on the variability observed in response to use of bronchodilator agents used in the treatment of asthma. Whether these polymorphisms alter the bronchoprotection response to beta(2)-agonist treatment in Spanish asthmatic population is unknown. The aim of this study was to investigate whether genetic polymorphisms within beta(2)AR gene modulate the clinical outcomes of the individual response to beta(2)-agonist therapy and the development of desensitization in Spanish asthmatic patients. In a prospective, case-control study were included 80 asthmatic patients. Based on the standard criteria, patients were classified into two groups: patients with tachyphylaxis and good responders to beta(2)-agonist therapy. DNA samples were genotyped for the Arg(16)Gly and Glu(27)Gln alleles within the beta(2)AR gene as well as in 64 control samples from blood donors. Arg(16) allele was slightly more frequent within the group with tachyphylaxis (P=0.039), whereas Gly(16) allele carriers were overrepresented within the group of good responders (59.7%, P=0.028). On the other hand, the allele frequency of Gln(27) and the proportion of Gln(27) carriers was higher within the group with tachyphylaxis (P=0.010 and 0.049, respectively) and Glu(27) allele carriers were overrepresented within the group of good responders (P=0.026). The Arg(16) and Gln(27) alleles were in strong linkage disequilibrium across this locus, resulting in the occurrence of disease haplotype. The predisposition to develop tachyphylaxis in our population seems to be linked to the Arg(16) and Gln(27) alleles and to the Arg(16)/Gln(27) risk haplotype (positive association between the presence of the Arg(16) and Gln(27) alleles and tachyphylaxis). The Arg(16) allele is perhaps overrepresented due to the strong linkage disequilibrium between both polymorphisms. The presence of the Glu(27) allele seems to be a protective factor against tachyphylaxis in this cohort study.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050497514

Download citation: RISBibTeXText

PMID: 16263254

DOI: 10.1016/j.rmed.2005.09.028


Related references

The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients. Iranian Journal of Allergy Asthma and Immunology 12(4): 383-390, 2013

Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma. Journal of Asthma 45(5): 383-388, 2008

Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor-mediated responses in human lung mast cells. British Journal of Pharmacology 152(3): 323-331, 2007

Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor expression in human lung. Pulmonary Pharmacology and Therapeutics 23(2): 71-77, 2010

Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype. American Journal of Medicine 109(2): 114-121, 2000

Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. British Journal of Pharmacology 138(3): 512-520, 2003

Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respiratory Medicine 96(3): 155-162, 2002

Infusion of beta2-adrenoceptor antagonists and inverse agonists restores histamine responses in transgenic mice with cardiac overexpression of the beta2-adrenoceptor. British Journal of Pharmacology 131(Proceedings Suppl.): 12P, 2000

Effects of the Gln27Glu- and the Arg16Gly-beta2-adrenoceptor polymorphisms on agonist-induced desensitization of beta2-adrenoceptor-mediated venodilation in vivo. British Journal of Clinical Pharmacology 55(4): 442, 2003

Beta2-Adrenoceptor polymorphism and asthma in Japan Application of PCR -RFLP to polymorphisms in the beta2-adrenoceptor. Research in Immunology 149(3): 267-268, March-April, 1998

Polymorphisms of beta2-adrenergic receptor gene in serbian asthmatic adults: effects on response to Beta-agonists. Molecular Diagnosis and Therapy 18(6): 639-646, 2014

Beta2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short and long-acting beta2-agonists. European Respiratory Journal 12(Suppl. 28): 372S, 1998

Stereoselectivity at the beta2-adrenoceptor on macrophages is a major determinant of the anti-inflammatory effects of beta2-agonists. Naunyn-Schmiedeberg's Archives of Pharmacology 362(2): 184-189, 2000

Desensitization of beta2-adrenoceptor and hypersensitization to phosphodiesterase inhibitors elicited by beta2-agonists in guinea pig eosinophils. Journal of Allergy and Clinical Immunology 106(5): 896-903, 2000

Desensitisation of beta2-adrenoceptor-mediated responses by long-acting beta2-agonists in human lung mast cells. British Journal of Pharmacology 135(Proceedings Suppl.): 266P, 2002